Pharma Technology Investment Trends - Senior Vice President, Small Precision Medicine Biopharma

An expert with experience as a senior vice president for a small pharmaceutical company discusses how they prioritized investments and what investment changes they would expect in the future. At this precision medicine focused company, this expert had budget authority in clinical trials and clinical activities, with some joint responsibility in the translational medicine area. They saw investments prioritized in the research tools space, specifically genomics, as well as in the clinical trial operations space. While some areas such as companion diagnostics, bioinformatics, and in vitro disease models were not core areas of investment, this expert imagined that they would receive greater investment in the future as this company became more established. They saw the greatest ROI in genomics and in activities that helped with patient recruitment. Relationships with vendors for trial recruitment and patient identification were a pain point for this expert, as were issues with supply chain shortages, as smaller companies are often more substantially impacted here. Events that would further alter their investment decisions related to the trend towards earlier cancer detection, decentralized care, and more patient education / patient access to resources.

‍